• VivoSim Labs on April 28, 2026 launched an AI prediction tool that uses its NAMkind human ileum and colon models to assess whether drug compounds may cause diarrhea in patients without animal testing.
• Model trained on dozens of compounds reached 96% predictive accuracy using 3D assay results from NAMkind intestinal tissues.
• Platform, branded VitroSense, ingests multiple intestinal assay endpoints to generate an overall diarrhea-risk readout for novel client compounds.
• VivoSim positioned tool as a screen for oncology programs, citing dose-limiting gastrointestinal toxicity risk in cancer drugs.
• Company also highlighted use in antibody-drug conjugate testing, including sensitivity to differences between antibody, payload, or full ADC effects on intestinal epithelium.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604280805PRIMZONEFULLFEED9708183) on April 28, 2026, and is solely responsible for the information contained therein.